About Iberia Pharmaceuticals India Ltd.
Incorporated in March 2013, Iberia Pharmaceuticals India Limited is an Indian pharmaceutical and derma cosmetics company engaged in the marketing and distribution of pharmaceutical, derma cosmetic and healthcare products. The Company offers a select portfolio of products across aesthetic dermatology, skin and hair care, cardio-diabetic care and general therapeutics, catering to a range of skin, hair, cardiovascular, diabetic and anti-aging concerns. Its portfolio includes prescription pharmaceutical products, derma cosmetics and over-the-counter healthcare and aesthetic products. The Company markets and distributes products under brands including Sesderma, Mediderma, Noreva, Dermpix, KeyCi and Metacare. Dermpix, KeyCi and Metacare are proprietary brands, while Sesderma and Mediderma originate from Spain and Noreva originates from France, for which the Company has exclusive distribution rights.
Under its dermatology portfolio, the Company offers products for conditions including hyperpigmentation, acne, skin rejuvenation, dull skin, wrinkles, intensive skin care and hair loss. Its flagship Sesderma brand uses formulation technologies including nanotechnology and liposomal formulations. The cardio-diabetic portfolio is marketed under the Metacare brand and addresses cardiovascular and metabolic conditions such as hypertension, dyslipidemia and diabetes, along with general wellness products. The Company also launched KeyCi, an online-exclusive proprietary brand, to strengthen its direct-to-consumer and e-commerce presence.
Since its incorporation, the Company has focused on the derma cosmetics segment and expanded its brand portfolio and geographical presence. In 2018, it became the exclusive distributor of Sesderma and Mediderma products across India, Nepal, Bangladesh, Bhutan, Sri Lanka, UAE and Myanmar. It launched its first proprietary brand, Dermpix, in 2021, followed by Metacare and KeyCi in 2025, and commenced the import and distribution of Noreva products in India as its exclusive distributor. The Company follows an asset-light business model, with proprietary products manufactured through third-party manufacturers according to its specifications and quality requirements, while focusing on branding, marketing and distribution.
As of March 31, 2026, the Company operated through a Pan-India network of 472 stockists under formal agreements and employed Medical Representatives to promote its products to healthcare professionals. It also sells selected products through online channels through its group company and online distribution partner, Iberia Skinbrands India Private Limited. The Company primarily serves the domestic market and has also exported its products to Nepal, Sri Lanka and Kenya. Its products are prescribed and recommended by healthcare professionals including dermatologists, cardiologists, trichologists and general physicians.
As of June 30, 2026, the Company had 343 permanent, full-time employees, including 301 employees in professional sales, 18 in marketing, and personnel across finance, product development, regulatory affairs, human resources, IT, logistics, production and other functions.
Competitive Strengths
- Presence in the cardio-diabetic segment.
- Extensive Pan-India distribution network.
- Growing digital and e-commerce presence.
- Strong presence in the dermatology segment.
- Experienced professional sales and management team.
- Quality standards and advanced formulation technologies.
- Exclusive distribution rights for established international brands.
- Established track record in the healthcare and derma cosmetics sector.
- Physician-focused marketing and Continuing Medical Education (CME) programmes.
